Dark

JSPR
Jasper Therapeutics, Inc. Common Stock
stock NASDAQ

At Close

Dec 26, 2025 3:59:30 PM EST

1.76USD-4.098%(-0.08)442,428

0.00Bid 0.00Ask 0.00Spread

Pre-market

Dec 26, 2025 9:01:30 AM EST

1.81USD-0.852%(-0.02)1,500

After-hours

Dec 23, 2025 4:54:30 PM EST

1.82USD-0.274%(-0.01)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 11, 2022

10:38AM EST 52 Weeks High And Low Article Benzinga

Dec 9, 2021

09:54PM EST Mid-Day Market Update: Crude Oil Down 1%; Inspira Technologies Shares Spike Higher Benzinga

Dec 8, 2021

08:35AM EST Jasper Therapeutics To Present Data On JSP191 Conditioning In SCID Patients At 2021 American Society Of Hematology Annual Meeting Dec. 12 Benzinga

08:30AM EST -- JSP191 is well tolerated with no treatment-related adverse events in dose-escalation study -- Single-agent conditioning with JSP191 is associated with engraftment, immune reconstitution, and clinical benefit GlobeNewswire Inc

Nov 15, 2021

09:26AM EST Jasper Therapeutics Reports Q3 2021 R&D Expenses $7.188M Benzinga

Nov 12, 2021

04:05PM EST Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced results for the quarter ended September 30, 2021, and provided a business update. GlobeNewswire Inc

Nov 9, 2021

11:45AM EST Jasper Therapeutics Announces Research Collaboration With AVROBIO To Evaluate JSP191 As Conditioning Agent In Clinical Studies Of Ex Vivo Lentiviral Gene Therapy Benzinga

08:00AM EST Jasper Therapeutics Announces Research Collaboration with AVROBIO GlobeNewswire Inc

Nov 8, 2021

09:06AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021 Benzinga

08:00AM EST Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that Bill Lis, Executive Chairman, and Chief Executive Officer, will present at the Credit Suisse 30th Annual Virtual Healthcare Conference on Wednesday, November 10, 2021, at 11:40 a.m. Pacific Time. GlobeNewswire Inc

05:25AM EST Credit Suisse Initiates Coverage On Jasper Therapeutics with Outperform Rating, Announces Price Target of $15 Benzinga

Oct 21, 2021

12:12PM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 21, 2021 Benzinga

12:11PM EDT William Blair Initiates Coverage On Jasper Therapeutics with Outperform Rating Benzinga

Oct 20, 2021

10:14AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2021 Benzinga

06:15AM EDT BMO Capital Initiates Coverage On Jasper Therapeutics with Outperform Rating, Announces Price Target of $19 Benzinga

Oct 18, 2021

07:34AM EDT The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs Benzinga

Oct 15, 2021

03:14PM EDT Jasper Therapeutics Shares Expected To Resume Trade At 3:15:55 p.m. EDT Benzinga

10:37AM EDT Mid-Morning Market Update: Markets Open Higher; Goldman Sachs Beats Q3 Expectations Benzinga

10:03AM EDT Shares of Jasper Therapeutics, Inc. (JSPR) are continuing their rally from Wednesday when the clinical-stage biotechnology company's stock rose on the news that Oppenheimer initiated coverage on the company with outperform rating. The stock are gaining over 30% on Friday morning. RTTNews

Oct 14, 2021

03:15PM EDT Why Jasper Therapeutics Stock Is Falling Today Benzinga

06:12AM EDT The following are some of the stocks making big moves in Thursday's pre-market trading (as of 06.00 A.M. EDT). RTTNews

Oct 13, 2021

03:11PM EDT Mid-Afternoon Market Update: Nasdaq Jumps 100 Points; Jasper Therapeutics Shares Spike Higher Benzinga

01:39PM EDT Mid-Day Market Update: Gold Surges 2%; Neuronetics Shares Plunge Benzinga

01:38PM EDT Why Jasper Therapeutics Stock Is Soaring Today Benzinga

01:38PM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2021 Benzinga

01:38PM EDT Mid-Morning Market Update: Markets Mixed; JPMorgan Posts Upbeat Earnings Benzinga

10:04AM EDT Jasper Therapeutics, Inc. (JSPR) shares are trading higher on Wednesday morning trade. Oppenheimer today initiated coverage on Jasper Therapeutics with outperform rating. On September 24, the shares have touched a year-to-date. Thereafter the shares started to decline however started to spike yesterday. RTTNews

04:55AM EDT Oppenheimer Initiates Coverage On Jasper Therapeutics with Outperform Rating, Announces Price Target of $21 Benzinga

Oct 12, 2021

08:13AM EDT The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology Benzinga

Oct 6, 2021

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Oct 3, 2021

10:48AM EDT Amgen Reported a Stake of 2.7M Shares in Jasper Therapeutics in a 13G Filing on Friday Benzinga

Oct 1, 2021

07:56AM EDT The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO Benzinga

Sep 30, 2021

07:43AM EDT The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug Benzinga

.dark-mode .H0Wq3k{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .H0Wq3k{ color: #333333; background-color: white; border: 2px solid #333333; }JSPRJasper Therapeutics, Inc. Common Stockstock NASDAQ

JSPR
Jasper Therapeutics, Inc. Common Stock
stock NASDAQ